United States set
language
Menu Shopping cart $0 Search
Manufactured by BioVendor

Human VEGF-A ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Vascular endothelial growth factor A, VPF
  • Species:Human
Cat. No. Size Price


RAF136R 96 wells (1 kit) $721,83
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Description

The Human VEGF-A ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of Human VEGF-A. The Human VEGF-A ELISA is for in vitro diagnostic use. Not for use in therapeutic procedures.

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate, Cell culture supernatant

Sample Requirements

50 µl/well

Shipping

On blue ice packs. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

15.6–1000 pg/ml

Limit of Detection

7.9 pg/ml

Intra-assay (Within-Run)

CV = 6.2%

Inter-assay (Run-to-Run)

CV = 4.3%

Dilution Linearity

serum 90%, EDTA plasma 110%, citrate plasma 90%, heparin plasma 108%, cell culture supernatant 91%

Specificity

The assay detects both natural and recombinant Human VEGF-A. Crossreactivity and interference of circulating factors of the immune systeme were evaluated by spiking these proteins at physiologically relevant concentrations into a Human VEGF-A positive serum. There was no crossreactivity detected, notably not with Human VEGF-B, VEGF-C, VEGF-D and PfGF. Interference was detected for VEGF-R1 at concentrations > 200 pg/ml, and not for VEGF-R2.

Summary

Features

  • RUO
  • calibration range 15.6-1000 pg/ml
  • limit of detection 7.9%
  • intra-assay CV = 6.2%
  • inter-assay CV = 4.3%

Research topic

Cytokines and chemokines and related molecules, Oncology

Summary

Normal tissue function depends on a regular supply of oxygen through the blood vessels. Understanding the formation of blood vessels has become the focus of a major research effort throughout the last decade. Vasculogenesis in the embryo is the process by which new blood vessels are generated de novo from primitive precursor cells. Angiogenesis is the process of new blood vessel formation from pre-existing vasculatures. It plays an essential role in development, normal tissue growth, wound healing, the female reproductive cycle (placental development, ovulation, corpus luteum) and also plays a major role in various diseases. Special interest is focused on tumor growth, since tumors cannot grow more than a few millimeters in size without developing a new blood supply. This process is described as tumor angiogenesis which is also essential for the spread and growth of tumor cell metastasis. One of the key molecules for angiogenesis and for the survival of the endothelium is vascular endothelial growth factor (VEGF-A). It is a specific endothelial cell mitogen and a strong vascular permeability factor (VPF). VEGF-A is a heparin-binding glycoprotein, secreted as a homodimer of 45 kDa by many different cell types. VEGF-A also causes vasodilation through the nitiric oxide synthase pathway in endothelial cells and can activate migration in monocytes. Many different splice variants of VEGF-A have been described, but VEGF165 is the most predominant protein and anchors with its heparin binding domain to extracellular matrix and to heparin sulfate. During the past few years, several other members of the VEGF family have been cloned, including VEGF-B, -C- and -D. In terms of vascular angiogenesis, which mainly is regulated by VEGF-A, lymphangiogenesis is mainly regulated by VEGF-C and -D.

Related Products Docs